JPH0337529B2 - - Google Patents
Info
- Publication number
- JPH0337529B2 JPH0337529B2 JP57166599A JP16659982A JPH0337529B2 JP H0337529 B2 JPH0337529 B2 JP H0337529B2 JP 57166599 A JP57166599 A JP 57166599A JP 16659982 A JP16659982 A JP 16659982A JP H0337529 B2 JPH0337529 B2 JP H0337529B2
- Authority
- JP
- Japan
- Prior art keywords
- cymetride
- amorphous
- simetride
- pvp
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IMOLVSPMDGCLMB-UHFFFAOYSA-N simetride Chemical compound COC1=CC(CCC)=CC=C1OCC(=O)N1CCN(C(=O)COC=2C(=CC(CCC)=CC=2)OC)CC1 IMOLVSPMDGCLMB-UHFFFAOYSA-N 0.000 claims description 35
- 229950007670 simetride Drugs 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- 239000000654 additive Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 description 13
- 238000002441 X-ray diffraction Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 4-n-propylphenoxy Chemical group 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57166599A JPS5955879A (ja) | 1982-09-27 | 1982-09-27 | 無定形シメトリド |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57166599A JPS5955879A (ja) | 1982-09-27 | 1982-09-27 | 無定形シメトリド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5955879A JPS5955879A (ja) | 1984-03-31 |
| JPH0337529B2 true JPH0337529B2 (zh) | 1991-06-05 |
Family
ID=15834274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57166599A Granted JPS5955879A (ja) | 1982-09-27 | 1982-09-27 | 無定形シメトリド |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5955879A (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0648937A (ja) * | 1992-04-07 | 1994-02-22 | Seitai Kagaku Kenkyusho:Kk | 経口投与に適する薬剤およびその製造方法 |
| WO2002100379A1 (fr) * | 2001-06-07 | 2002-12-19 | Takeda Chemical Industries, Ltd. | Procede de preparation d'une dispersion solide |
-
1982
- 1982-09-27 JP JP57166599A patent/JPS5955879A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5955879A (ja) | 1984-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5048871B2 (ja) | キノリン誘導体含有医薬組成物 | |
| JP2735903B2 (ja) | イブプロフエン沸騰製剤 | |
| US4673564A (en) | Sustained release pharmaceutical composition of solid medical material | |
| KR101632079B1 (ko) | 디히드로피리딘 칼슘 채널 길항제를 함유하는 약제학적 조성물 및 그것의 제조방법 | |
| KR101584674B1 (ko) | 바제독시펜 아세테이트 제형 및 이의 제조방법 | |
| NZ502062A (en) | Process for manufacturing paroxetine solid dispersions | |
| WO2007011018A1 (ja) | 口腔内速崩壊性錠 | |
| JP3518601B2 (ja) | エバスタイムまたはその類似体に基づく医薬組成物 | |
| WO2018199282A1 (ja) | エンザルタミドを含有する経口投与用医薬組成物 | |
| KR100908418B1 (ko) | 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법 | |
| US6365196B1 (en) | Controlled release solid dosage forms of lithium carbonate | |
| JP6063379B2 (ja) | 固形医薬組成物 | |
| JPH03275634A (ja) | バイオアベイラビリティが高められた吸着質製剤 | |
| JPS61183225A (ja) | ９，１０‐ジヒドロ麦角アルカロイド含有医薬組成物 | |
| JPH0337529B2 (zh) | ||
| KR20190007896A (ko) | 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 포함하는 구강 붕해정 및 이의 제조방법 | |
| WO2007049626A1 (ja) | カベルゴリン含有経口固形製剤 | |
| JP2841857B2 (ja) | 長期間安定な経口用医薬製剤 | |
| JPH0347124A (ja) | 経口吸収用製剤 | |
| JP5900702B2 (ja) | 経口投与用医薬組成物 | |
| JPH08325142A (ja) | ヨウ化イソプロパミド含有製剤 | |
| JP3232687B2 (ja) | イミダプリル含有製剤 | |
| CA3094550A1 (en) | Instant release pharmaceutical preparation of anticoagulant and preparation method therefor | |
| EP4279075B1 (en) | A pharmaceutical composition comprising elagolix | |
| EP4279075A1 (en) | A pharmaceutical composition comprising elagolix |